Monday, April 14, 2008 9:02:02 AM
Company Release - 04/14/2008 08:30
link:
http://www.snl.com/irweblinkx/news.aspx?IID=4104784
SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 American Association of Cancer Research (AACR) Annual Meeting being held April 12 - 16 in San Diego.
In the poster titled "The inhibition of radiation repair by ranpirnase +/- I-buthionine sulfoximide on lung cancer," Dr. Lee provided pre-clinical evidence that ONCONASE +/- I-buthionine sulfoximide significantly increased the radiation-induced growth delay of lung tumors in vivo without increases in skin reaction, compared to radiation alone. Additionally, in vivo and in vitro data presented indicated that ONCONASE significantly increased apoptosis (programmed cell death) in several human non-small cell lung cancer (NSCLC) cell lines (A549, NCI-H1975 and HOP-62). Dr. Lee and his team of researchers also showed that the radiation repair mechanisms known as sub-lethal damage repair (SLDR) and potentially lethal damage repair (PLDR), which lead to radiation resistance in tumors, were significantly inhibited by ONCONASE in vitro.
"Our research suggests potential utility of ONCONASE as a radiotherapy enhancer for the treatment of NSCLC patients," said Dr. Lee. "It is important to overcome PLDR as it can ultimately lead to radiation resistance. One of our key findings is the inhibiting impact of ONCONASE on the PLDR mechanism, which is a pre-requisite to developing a radiotherapy enhancer."
Kuslima Shogen, Alfacell's chief executive officer, added: "This work by Dr. Lee and his team provides further evidence of the potential for ONCONASE to mitigate the resistance that often develops in, and confounds the treatment of NSCLC."
About ONCONASE(R)
ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact: Investor Contact:
David Schull or Wendy LauTimothy EngelRusso PartnersRusso Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.comTimothy.Engel@russopartnersllc.comWendy.Lau@russopartnersllc.com
SOURCE Alfacell Corporation
Recent ACEL News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 08:39:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:31:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:36:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:32:51 PM
- Accel Entertainment Announces Q1 2024 Operating Results • Business Wire • 05/08/2024 08:30:00 PM
- Accel Entertainment, Inc. to Announce First Quarter 2024 Financial Results • Business Wire • 04/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:33:01 PM
- Accel Entertainment Announces 2023 Operating Results • Business Wire • 02/28/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:18:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 09:23:28 PM
- Accel Entertainment, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/14/2024 12:30:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:36:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 07:37:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 12:01:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 10:32:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 10:32:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 10:32:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:35:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:35:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:35:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:35:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:34:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:34:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 12:09:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 02:22:43 AM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM